Skip to content
Start consultationStart
Weight loss · Barcelona

Semaglutide in Barcelona, online

An EU-licensed doctor reviews your case and, if eligible, issues an electronic prescription you can collect at a pharmacy in Barcelona.

From€25/ 28 days

Consultation price. The medicine is paid at your pharmacy.

  • Prescription only, if a doctor approves
  • Doctor-reviewed renewals
  • Full refund if not approved
Start consultation
Semaglutide

Licensed EU doctors

Every case read by a registered doctor.

Reply in under 2 hours

On average, in writing, no video call.

Pay only if approved

Not approved? Refunded in full, automatically.

Rated excellent on Trustpilot

4.8 from 540+ independent reviews.

Valid across the EU

E-prescription accepted at EU pharmacies.

Local facts

Semaglutide consultations in Barcelona

Available toResidents of Spain
LanguagesSpanish and English
Doctor replyUnder 2 hours on average
Collected atPharmacies in Spain · QR e-prescription
About the medicine

What it is and how it works

Semaglutide is a GLP-1 receptor agonist, a medication that mimics a natural hormone your gut releases after eating. It reduces appetite, slows gastric emptying and helps maintain sustained weight loss when combined with supervised nutrition and activity changes.

It's prescribed alongside changes to diet and activity, as part of a medically supervised plan, not on its own, and not as a shortcut. A licensed EU doctor decides whether it's appropriate and safe for you.

Who it is for

  • Adults with a BMI of 30 or above, or 27 to under 30 with a weight-related condition.
  • One injection under the skin, once a week, on the same day each week.

Safety summary

Nausea and vomiting are very common; severe stomach pain can signal pancreatitis.

Read the safety summary
Pricing

One consultation, one clear price

You pay for the doctor's consultation. If a prescription is issued, the medicine is paid at your own pharmacy.

  • Consultation reviewed by an EU-licensed doctor
  • Private follow-up in the in-app chat
  • Full refund if the doctor does not approve
Plan or one-off

Weight loss

Monthly planCancel anytime€25/ 28 daysOne-off28-day treatment€35once
  • First consultation included
  • Renewals reviewed by your doctor
  • Ongoing care in your private chat
  • Cancel anytime
Start consultation

Full refund if a review is not approved

FAQs

Your questions answered

Semaglutide16 questions
What is semaglutide and how does it support weight management?
Semaglutide is a GLP-1 receptor agonist that mimics a natural gut hormone. It reduces appetite, slows gastric emptying, and helps maintain sustained weight loss when combined with supervised nutrition and activity changes.
In the EU it is indicated as an adjunct in adults with BMI ≥ 30, or ≥ 27 with metabolic comorbidities. It is not a cosmetic treatment: the licensed doctor reviews your history, current medication and goals before deciding whether it is safe for you.
More questions
Mild nausea, bloating and constipation, especially when starting or increasing the dose. Most settle within 1–2 weeks. Serious effects are uncommon; your doctor explains red flags and how to reach them through the private in-app chat.
The dose is escalated over 16 weeks. Appetite changes typically appear in 2–4 weeks; clinically meaningful weight loss is assessed at 3 months. Our doctors follow up quarterly before renewing the prescription.
Weight tends to come back. This was measured directly in the STEP 4 trial. Everyone in it spent 20 weeks building up to the 2.4 mg dose, then half continued and half were switched to a dummy injection. Over the following 48 weeks the group who continued lost a further 7.9% of body weight on average, while the group who stopped regained 6.9%. That is a gap of 14.8 percentage points. Semaglutide is therefore used as a long-term treatment rather than a short course, and any decision to stop should be discussed with the prescribing doctor.
The full dose is not reached until week 17. The product information sets out a deliberate 16-week build-up, starting at 0.25 mg and stepping up every four weeks, purely to reduce nausea and other stomach side effects. Some people notice reduced appetite during those early weeks, but the maintenance dose of 2.4 mg only begins afterwards. The pivotal STEP 1 trial measured its main result at 68 weeks, which is around 16 months, so this is measured in months rather than weeks. Your prescriber may slow the build-up further if side effects are troublesome.
NHS guidance advises avoiding alcohol, because it can worsen side effects such as feeling or being sick. Nausea is the most frequently reported side effect of semaglutide, affecting more than one in ten people, and it is most noticeable during the dose build-up when the stomach is already adjusting. Alcohol also adds calories that work against a reduced-calorie diet, and it can affect blood sugar, which matters more if you also take insulin or a sulfonylurea. If you drink regularly, raise it with the prescribing doctor rather than deciding alone.
Write to your doctor in the private chat in your account: describe what you notice and when it started. The doctor can adjust the plan, pause it or suggest another option. If you have severe symptoms such as difficulty breathing, swelling of the face or chest pain, call 112 or go to an emergency department straight away.
It depends on what you take. List every medicine, supplement and herbal product in the questionnaire, including ones you use only occasionally. The doctor checks for interactions before prescribing, and your pharmacist checks again when you collect Semaglutide.
The doctor can consider another weight-management medicine authorised in the EU, or a plan built on nutrition and activity alone. Some people are better served by an in-person obesity clinic or by their own doctor, and the doctor explains why when that is the case.
Before each renewal the doctor reviews your weight, side effects and how you feel, and decides whether to continue, change the dose or stop. Changes are never automatic. You can also write in the private chat between reviews.
Yes. Hi-Doctor runs 100 % online across the EU, so if you live in Barcelona you can fill in the questionnaire and receive the medical review without travelling. The electronic prescription issued by the licensed doctor is valid in any EU pharmacy under Directive 2011/24/EU; in Spain it is dispensed directly from the prescription QR.
Adults with BMI ≥ 30, or ≥ 27 with comorbidities (hypertension, type-2 diabetes, dyslipidaemia). The doctor reviews your history, current medication and goals before proposing any treatment. It is not a cosmetic programme.
The private electronic prescription (Receta Médica Privada Electrónica) is issued by a licensed doctor in Spain. It is a PDF carrying every field required by EU Directive 2011/24/EU (patient, prescriber with country of registration, active ingredient, dose), which makes it legally recognised across all 27 EU member states. In Spanish pharmacies it is dispensed from the QR; outside Spain, the pharmacist dispenses the locally marketed equivalent of the same active ingredient.
1) Fill in an online medical questionnaire in about 4 minutes. 2) The plan is €25/month for weight loss or €15/month (billed €45 every 90 days) for hair growth; sexual health is €35 per consultation and a skin consultation is €40. 3) An EU-licensed doctor reviews your case and, if appropriate, issues an electronic prescription. 4) Collect it at any EU pharmacy. If the review is not approved, the applicable fee is refunded in full.
The plan is €25/month for weight loss or €15/month (billed €45 every 90 days) for hair growth; a one-off sexual-health consultation is €35 and a skin consultation covering acne, rosacea, melasma and ageing skin is €40. Each includes a licensed doctor's review and an electronic prescription if approved. If the review is not approved, the applicable fee is refunded in full. Medication is paid for separately at the pharmacy at the price it sets.
Behind the scenes

How your doctor decides

Your answers

A licensed doctor reads your full questionnaire.

Medical judgement

The decision is clinical, never an algorithm.

Clear outcome

Approved with an e-prescription, or refunded in full.

Also for Weight loss

Related medicines

Medicine information and safety

How does Semaglutide work?

It copies a natural gut hormone. Semaglutide is a close copy of GLP-1, a hormone your gut releases after you eat. It shares about 94% of the structure of the natural hormone, so it fits the same docking points on cells, but it is built to last much longer in the body.

It acts on appetite centres. Once attached to those docking points, semaglutide signals the parts of the brain that control hunger, including the hypothalamus and brainstem. In clinical studies people reported feeling full sooner, staying full for longer, feeling less hungry, and having fewer and weaker food cravings.

Eating less drives the change. Because appetite falls, most people take in fewer calories without consciously trying, and that gap is what produces weight change over months. Semaglutide also slightly slows how fast the stomach empties early after a meal, and prompts insulin release only when blood sugar is high.

How to use Semaglutide

One injection, same day weekly. Semaglutide for weight management is injected under the skin once a week, at any time of day, with or without food. Most people pick a fixed day and set a reminder, because the weekly rhythm is easy to lose track of.

Choose and rotate injection sites. The approved sites are the abdomen, the thigh and the upper arm. The site can be changed from week to week. Rotating between sites is standard practice for injections under the skin and helps avoid repeated irritation in one spot.

Use a fresh needle every time. Attach a new needle for each injection and remove it afterwards, storing the pen without a needle attached. The product information says this helps prevent blocked needles, contamination, infection, leaking solution and inaccurate dosing. Compatible needles are 30G, 31G or 32G.

Check the liquid before injecting. Look at the solution first. It should be clear and colourless. The product information says not to use the pen if the liquid looks otherwise, or if it has been frozen at any point. Pens must never be shared between people.

Follow the pack instructions exactly. Each pen type has its own instructions for use inside the carton, and the product information asks patients to read them carefully before the first injection. With a single-dose pen you press it firmly against the skin until the yellow bar stops moving.

If you miss a dose. Take a missed dose as soon as possible, as long as fewer than five days have passed. If more than five days have gone by, skip it and take the next dose on the normal day. Ask the prescriber before restarting after several missed doses.

Moving your weekly dosing day. The day of the week can be changed if needed, provided at least three days, meaning more than 72 hours, separate one dose from the next. After moving to a new day, carry on with the once-weekly pattern from there.

Storing the pen correctly. Before first use, keep the pen in the fridge between 2°C and 8°C, away from the cooling element, and never freeze it. Keep the cap on to protect it from light. After first use a FlexTouch pen keeps for six weeks below 30°C.

Common side effects

Stop and get urgent medical help if (seek medical help immediately): Severe, persistent stomach pain, often spreading through to the back, Sudden loss of vision, including partial loss in one eye, Swelling of the face, lips, tongue or throat, or trouble breathing, Severe stomach pain with bloating, vomiting and no bowel movements, Pain under the right ribs with fever or yellowing skin, Vomiting or diarrhoea so severe that you cannot keep fluids down, Shakiness, confusion or sweating if you also take insulin or a sulfonylurea

Very common (very common (≥1/10)): Feeling sick (nausea), Being sick (vomiting), Diarrhoea, Constipation, Stomach pain, Headache, Tiredness

Common (common (≥1/100 to <1/10)): Dizziness, Altered sense of taste, Unusual skin sensations such as tingling or numbness, Indigestion, heartburn or acid reflux, Inflammation of the stomach lining (gastritis), Burping, wind or a bloated stomach, Gallstones, Hair loss, Reactions where the injection was given, Low blood sugar, in people who also have type 2 diabetes, Worsening of diabetic eye disease, in people with type 2 diabetes

Uncommon (uncommon (≥1/1,000 to <1/100)): Inflammation of the pancreas (acute pancreatitis), The stomach emptying more slowly than usual, A faster heart rate, Low blood pressure, Feeling dizzy on standing up (orthostatic hypotension), Raised amylase and lipase, two pancreatic enzymes, in blood tests

Rare (rare (≥1/10,000 to <1/1,000)): Severe allergic reaction affecting the whole body (anaphylaxis), Swelling of the face, lips, tongue or throat (angioedema)

Very rare (very rare (<1/10,000)): Sudden loss of vision caused by damage to the optic nerve

Reported, frequency not known (frequency not known): Blockage of the bowel (intestinal obstruction)

Do not use Semaglutide if

  • You have ever had an allergic reaction to semaglutide or any ingredient in the pen
  • You are pregnant, planning a pregnancy within the next two months, or breastfeeding
  • You have type 1 diabetes, because semaglutide is not a substitute for insulin
  • You already take another GLP-1 receptor agonist, as the combination has not been evaluated
  • You take another prescription weight-management medicine at the same time
  • You have severe kidney impairment, including end-stage kidney disease
  • You have severe liver impairment
  • You have severe gastroparesis, a condition where the stomach empties very slowly
  • You have congestive heart failure classed as New York Heart Association class IV
  • You have type 2 diabetes with uncontrolled or unstable diabetic eye disease

Medicines and substances that interact

  • Warfarin and other coumarin blood thinners: Cases of a reduced INR clotting measure have been reported alongside semaglutide. Prescriber arranges more frequent INR blood tests when semaglutide is started.
  • Insulin: Combined with semaglutide in type 2 diabetes, the risk of low blood sugar rises. Prescriber may lower the insulin dose at the start and monitor blood sugar.
  • Sulfonylureas (e.g. gliclazide): Also raise the risk of low blood sugar when taken alongside semaglutide. Prescriber may reduce the sulfonylurea dose when semaglutide is introduced.
  • Oral medicines needing fast absorption: Semaglutide slows stomach emptying, which could in principle affect how they are absorbed. Prescriber uses caution and reviews whether timing or monitoring needs changing.
  • Combined oral contraceptives: No clinically relevant change; levonorgestrel exposure rose 20%, ethinylestradiol was unaffected. No dose change needed. Contraception is advised while taking semaglutide.
  • Paracetamol: Peak levels fell 23% with semaglutide 1 mg, but total exposure was unchanged. No dose adjustment of paracetamol is required.
  • Atorvastatin: Peak level fell 38% but overall exposure was unchanged, judged not clinically relevant. No dose adjustment is required.
  • Digoxin and metformin: Semaglutide did not change overall exposure or peak levels of either medicine. No dose adjustment is required.

References

  1. Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen: Summary of Product Characteristics electronic medicines compendium (emc), 2026
  2. Wegovy: Annex I Summary of Product Characteristics (EU product information) European Medicines Agency, 2026
  3. Wegovy (semaglutide): European Public Assessment Report overview European Medicines Agency, 2026
  4. Ozempic (semaglutide) solution for injection: Summary of Product Characteristics, type 2 diabetes indication electronic medicines compendium (emc), 2026
  5. STEP 1: Once-Weekly Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine (Wilding JPH et al., 384:989-1002), 2021
  6. STEP 4: Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance JAMA (Rubino D et al., 325:1414-1425), 2021
  7. SELECT: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes New England Journal of Medicine (Lincoff AM et al., 389:2221-2232), 2023
  8. Semaglutide (Wegovy, Ozempic, Rybelsus): NHS medicines A to Z National Health Service (UK), 2026
  9. Wegovy FlexTouch: authorisation and supply classification record AEMPS CIMA (Spain), 2026
  10. Ficha técnica Wegovy 2,4 mg FlexTouch: EU Summary of Product Characteristics, section 4.8 adverse reaction table AEMPS CIMA (Spain), 2026
  11. Situación de financiación de medicamentos: Wegovy 2,4 mg, national code 758089 Ministerio de Sanidad (Spain), 2023
  12. G-BA implements the statutory prescribing exclusion for the weight-loss medicine Wegovy Gemeinsamer Bundesausschuss (Germany), 2024
  13. Obésité: de nouveaux médicaments peuvent être pris en charge dans des conditions encadrées Assurance Maladie / ameli.fr (France), 2026
  14. Wegovy niet vergoeden uit het basispakket: GVS advice on semaglutide for obesity Zorginstituut Nederland, 2024
  15. Medicines to treat obesity: reimbursement status of semaglutide in Ireland Health Service Executive (Ireland), 2026
  16. Obwieszczenie Ministra Zdrowia: wykaz refundowanych leków (pharmacy reimbursement list) Ministerstwo Zdrowia (Poland), 2026
  17. Rejestr Produktów Leczniczych: Wegovy (semaglutidum) registration record, ATC A10BJ06 Rejestry Medyczne / e-Zdrowie (Poland), 2026
  18. Behandlungspfad Übergewicht & Adipositas: case-by-case consideration of weight-reduction medicines Dachverband der österreichischen Sozialversicherung (Austria), 2026
  19. Warning on falsified GLP-1 receptor agonists: prescription status and pharmacy-only supply in Austria Bundesamt für Sicherheit im Gesundheitswesen (BASG, Austria), 2026
  20. Nieuwigheden geneesmiddelen: Wegovy commercialised in Belgium, not reimbursed for obesity Belgisch Centrum voor Farmacotherapeutische Informatie (BCFI/CBIP), 2025
  21. Wegovy FlexTouch: INFARMED market authorisation notice and semaglutide safety communication INFARMED, I.P. (Portugal), 2026
  22. Nuovi farmaci per il diabete e l'obesità: AIFA guide to responsible use, Wegovy class C classification Agenzia Italiana del Farmaco (AIFA), 2026
  23. Mounjaro (tirzepatide): European Public Assessment Report overview European Medicines Agency, 2026
  24. Saxenda (liraglutide): European Public Assessment Report overview European Medicines Agency, 2026
  25. Saxenda 6 mg/mL solution for injection: Summary of Product Characteristics electronic medicines compendium (emc), 2026
  26. Xenical (orlistat): European Public Assessment Report overview European Medicines Agency, 2026

Also available in

Ozempic
Ozempic
Wegovy
Wegovy
Rybelsus
Rybelsus
Online doctor by city

Also available in

SevillaMálagaCórdobaGranadaJerez de la FronteraAlmeríaHuelvaCádizJaénMarbellaZaragozaHuescaTeruelOviedoGijónAvilés

Start your treatment journey

A doctor replies in under 2 hours on average.

Start consultationNo charge unless a doctor approves your treatment.
All content on this page has been medically reviewed by: Dr. Alejandro Infante, General medicine, on 27 July 2026. Registration: 080869277 View profile

Pay nothing if a doctor doesn't approve your treatment. Every consultation is fully refundable. How refunds work